Synthetic Biologics appoints Michael Kaleko scientific director
This article was originally published in Scrip
Synthetic Biologics, a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, has named Dr Michael Kaleko scientific director. Dr Kaleko has worked in the gene therapy field since its inception in the 1980s, and until 2010 served as CSO of a company he co-founded in 2002 and sold in 2005, Advanced Vision Therapies. Prior to that, he co-directed research for 11 years at Genetic Therapy, a Novartis company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.